Table 1.
Correlation between LOC285194 expression and clinicopathologic characteristics of 142 ESCC patients
| Variables | LncRNA LOC285194 subgroup a | P b value | |
|---|---|---|---|
| Low | High | ||
| All cases | 71 | 71 | |
| Gender | |||
| Male | 49 (69.1%) | 45 (63.3%) | 0.478 |
| Female | 22 (30.0%) | 26 (36.7%) | |
| Age (years) | 0.614 | ||
| ≤55 | 8 (11.3%) | 10 (14.1%) | |
| >55 | 63 (88.7%) | 61 (85.9%) | |
| Tumor size (cm) | 0.002* | ||
| ≤5 | 39 (55.0%) | 57 (80.3%) | |
| >5 | 32 (45.0%) | 14 (19.7%) | |
| Tumor location | 0.573 | ||
| Cervical/upper thoracic | 6 (8.5%) | 8 (11.3%) | |
| Middle/lower thoracic | 65 (91.5%) | 63 (88.7) | |
| Histologic grade | 0.022* | ||
| G1 | 6 (8.5%) | 7 (9.9%) | |
| G2 | 36 (50.7%) | 50 (70.4%) | |
| G3/G4 | 29 (40.8%) | 14 (19.7%) | |
| Smoking status | 0.603 | ||
| Ever/current | 28 (39.4%) | 25 (35.2%) | |
| Never | 43 (60.6%) | 46 (64.8%) | |
| Alcohol consumption | 0.206 | ||
| Ever/current | 17 (23.9%) | 11 (15.5%) | |
| Never | 54 (76.1%) | 60 (84.5%) | |
| T status | 0.27 | ||
| T1/2 | 18 (25.4%) | 24 (33.8%) | |
| T3/4 | 53 (74.6%) | 47 (66.2%) | |
| N status | 0.013* | ||
| N0M0 | 23 (32.4%) | 39 (54.9%) | |
| N1M0 | 22 (31.0%) | 19 (26.8%) | |
| M1-lymc | 26 (36.6%) | 13 (18.3%) | |
| M status | 0.015* | ||
| M0 | 45 (63.4%) | 58 (81.7%) | |
| M1-lym | 26 (36.6%) | 13 (18.3%) | |
| Clinical stage | 0.018* | ||
| IandII | 26 (36.6%) | 40 (56.3%) | |
| III | 45 (63.4%) | 31 (43.7%) | |
| CRT response | 27 | 28 | 0.001* |
| PathCRd | 4 (29.6%) | 16 (67.9%) | |
| Less than PathCR | 23 (70.4%) | 12 (32.1%) | |
aMedian expression level was used as a cutoff to divide the 142 patients into LOC285194 low group (n = 71) and LOC285194 high group (n = 71). bChi-square test. cM1-lym, distant lymph node metastasis. dPathCR, pathologic complete response. *p < 0.05.